Publication date: Jun 27, 2025
Pembrolizumab has revolutionised the treatment of melanoma. Immune checkpoint inhibitors (ICI) are well tolerated in trials, but the real-world incidence of toxicities and their management are not well described. We investigated the incidence and management of toxicities in New Zealand. A retrospective review was conducted on patients with metastatic melanoma treated with pembrolizumab at Wellington and Waikato Hospitals between March 2016 and September 2021. The occurrence, severity and management of toxicities was recorded. Of the 273 patients, 42% experienced treatment-related toxicity. Seventy-five percent of toxicities were grade 1/2 (mild), 25% grade 3/4 (moderate or life-threatening) and
Semantics
| Type | Source | Name |
|---|---|---|
| drug | DRUGBANK | Pembrolizumab |
| disease | MESH | melanoma |
| pathway | KEGG | Melanoma |
| disease | MESH | Skin Neoplasms |
Original Article
(Visited 2 times, 1 visits today)